title: Intensive community pharmacy intervention had little impact on triptan consumption: a randomized controlled trial.
abstract: OBJECTIVE
  To evaluate the impact of an intensive pharmaceutical care campaign targeting inappropriate use of triptans.
  
  
  METHODS
  Randomized controlled trial.
  
  
  METHODS
  22 community pharmacies in the County of Funen, Denmark.
  
  
  METHODS
  A total of 1123 triptan users at intervention pharmacies and 1340 at control pharmacies.
  
  
  METHODS
  Intervention pharmacy staff received information on migraine and other types of headache, detection of inappropriate triptan use and other drug-related problems, and techniques for establishing a dialogue with patients. Intervention consisted of a folder and a structured dialogue with the pharmacy staff. The folder included questions aimed at detecting overuse and inappropriate triptan use.
  
  
  METHODS
  Change in average triptan consumption in doses per month measured by means of a prescription database with information on all purchases of reimbursed drugs at the level of the individual patient.
  
  
  RESULTS
  Overall, intervention had no statistically significant short-term impact on patients' consumption of triptans either among incident users (intervention/control ratio 1.02; 95% confidence interval 0.95 to 1.12), or among prevalent users (1.02; 0.97 to 1.08). No effects were observed after 6 and 9 months, apart from a possible borderline effect after 9 months among prevalent users with intermediate triptan consumption (0.93; 0.87 to 1.00).
  
  
  CONCLUSIONS
  The pharmaceutical care campaign did not reduce the use of triptans.
authors.affiliation: Research Unit for General Practice, University of Aarhus, Aarhus, Denmark. js@alm.au.dk
authors.forename: Jens
authors.initials: J
authors.lastname: Søndergaard
authors.forename: Annette
authors.initials: A
authors.lastname: Foged
authors.forename: Jakob
authors.initials: J
authors.lastname: Kragstrup
authors.forename: David
authors.initials: D
authors.lastname: Gaist
authors.forename: Lars Freng
authors.initials: LF
authors.lastname: Gram
authors.forename: Søren Hein
authors.initials: SH
authors.lastname: Sindrup
authors.forename: Hans Ulrik Schaffalizky de
authors.initials: HU
authors.lastname: Muckadell
authors.forename: Bente Overgaard
authors.initials: BO
authors.lastname: Larsen
authors.forename: Hanne
authors.initials: H
authors.lastname: Herborg
authors.forename: Morten
authors.initials: M
authors.lastname: Andersen
mesh_terms: D000328:Adult; D003718:Denmark; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004363:Drug Utilization / Q000706:statistics & numerical data; D004513:Education, Pharmacy, Continuing; D005260:Female; D020773:Headache Disorders / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D010353:Patient Education as Topic; D010594:Pharmacies; D010595:Pharmacists; D010818:Practice Patterns, Physicians'; D011369:Professional-Patient Relations; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D018170:Sumatriptan / Q000008:administration & dosage* / Q000009:adverse effects; D011795:Surveys and Questionnaires; D014662:Vasoconstrictor Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D018170:Sumatriptan